Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin(SOX)+bevacizumab regimen for advanced colorectal cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000015446
- Lead Sponsor
- Kyoto-Katsura Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
1.With a history of severe drug allergic response 2.Pregnant or lactating women or women of childbearing potential. 3. Uncontrolled infection. 4. With a history of severe systemic diseases. 5.Evidence of cardiovascular abnormalities. 6.Evidence of gastrointestinal bleeding 7.Evidence of sensory disturbance 8.Evidence of severe diarrhea 9. Evidence of ascites or pleural effusion needed to treat. 10. Evidence of gstrointestinal obstraction. 11.Evidence of peritoneal dissemination 12. Evidence of brain metastasis 13. History of hematemesis 14. History of cardiovascular events including unstable angina, cardiac infarction, cerebral infarction and pulmonary embolism 15.Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks. 16.Evidence of bleeding diathesis or coagulopathy. 17.Administering antithrombotic drugs 18. blood transfusion within 2 weeks. 19. Multiple primary cancers within 5 years. 20. patients with administration of steroids. 21. Patients who have active hepatitis type B. 22. contraindication of S-1, L-OHP, BV administration 23.Other conditions not suitable for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method